Ideaya announces positive interim phase 2 monotherapy expansion data for ide397 a potential first-in-class mat2a inhibitor in mtap-deletion urothelial and lung cancer

~39% overall response rate (orr): 1 cr and 6 prs (2 awaiting confirmation) by recist 1.1 out of 18 evaluable mtap-deletion urothelial and nsclc patients ~94% disease control rate (dcr): 1 cr and 6 prs and 10 sd by recist 1.1 ~78% of patients with tumor shrinkage: 14 patients observed tumor shrinkage ~81% ctdna molecular response rate (mrr): 13 of 16 patients with > 50% ctdna reduction ae profile: ~5.6% drug-related grade > 3 aes and no drug-related saes or discontinuations at 30 mg once-a-day expansion dose ide397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma sam pharmacodynamic reduction associated with preclinical tumor regressions ~48k u.s. annual incidence of mtap-deletion urothelial cancer and nsclc, with high unmet need and no fda-approved therapies for mtap-deletion solid tumors investor webcast scheduled for today, monday, july 8, 2024, at 8:00 am et south san francisco, calif. , july 8, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced positive clinical data for the ide397 phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase (mtap)-deletion urothelial and non-small cell lung cancer (nsclc) patients.
MAT Ratings Summary
MAT Quant Ranking